Correction: Clinical impact of measurable residual disease monitoring by ultradeep next generation sequencing in NPM1 mutated acute myeloid leukemia

PDF  |  How to cite

Oncotarget. 2019; 10:617-617. https://doi.org/10.18632/oncotarget.26610

Metrics: PDF 746 views  |   ?  

Nikhil Patkar1,*, Rohan Kodgule1,5,*, Chinmayee Kakirde1, Goutham Raval1, Prasanna Bhanshe1, Swapnali Joshi1, Shruti Chaudhary1, Y. Badrinath1, Sitaram Ghoghale1, Shraddha Kadechkar1, Syed Hasan Khizer2, Sadhana Kannan3, Dhanalaxmi Shetty4, Anant Gokarn2, Sachin Punatkar2, Hasmukh Jain2, Bhausaheb Bagal2, Hari Menon6, Manju Sengar2, Navin Khattry2, Prashant Tembhare1, Papagudi Subramanian1 and Sumeet Gujral1

1 Haematopathology Laboratory, ACTREC, Tata Memorial Centre, Navi Mumbai, India
2 Adult Haematolymphoid Disease Management Group, Tata Memorial Centre, Mumbai, India
3 Biostatistics, ACTREC, Tata Memorial Centre, Navi Mumbai, India
4 Dept of Cytogenetics, ACTREC, Tata Memorial Centre, Navi Mumbai, India
5 Homi Bhabha National Institute, Training School Complex, Mumbai, India
6 Haemato-Oncology, CyteCare Cancer Hospital, Bangalore, India
* These authors contributed equally to this work

Published: January 15, 2019

This article has been corrected: The correct Funding information is given below:


This work was supported by the Wellcome Trust/DBT India Alliance Fellowship [grant number IA/CPHI/14/1/501485] awarded to Dr Nikhil Patkar. Initial part of the study (8 colour FCM) was funded by a Lady Tata Memorial Trust Grant awarded to Prof Navin Khattry.

Original article: Oncotarget. 2018; 9:36613-36624. DOI: https://doi.org/10.18632/oncotarget.26400.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 26610